Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment
复制标题
DOI：
10.1097/00001756-200103260-00045
复制
发表时间：
2001-03-26
期刊：
影响因子：
1.7
通讯作者：
Nordberg, A
中科院分区：
文献类型：
--
作者：
Arnáiz, E;Jelic, V;Nordberg, A
本研究的目的是评估糖代谢降低（rCMRGlu）和认知功能是否可以预测轻度认知障碍（MCI）受试者中阿尔茨海默病（AD）的发展。20名MCI患者接受了通过PET测量的rCMRGlu的基线和随访调查，以及通过神经心理学测试评估测量的认知功能。受试者接受了平均36.5个月的临床随访。在第二次临床评估后获得两组。9例患者被诊断为AD并被分类为进行性MCI（P-MCI），而11例患者保持临床稳定并被分类为稳定型MCI（S-MCI）。两个亚组之间的人口统计学变量或基线MMSE无差异。Logistic回归分析显示，左颞顶区的rCMRGlu和区组设计的成绩是预测AD未来发展的最有效的两个变量。这些组合措施给出了最佳的90%正确分类率，而仅rCMRGlu或神经心理学分别给出了75%和65%的正确分类。测量颞顶脑代谢和视觉空间功能可能有助于预测MCI患者向AD的演变。NeuroReport 12：851-855（C）2001 Lippincott威廉姆斯和威尔金斯。
The objective of this study was to assess whether reduced glucose metabolism (rCMRGlu) and cognitive functioning could predict development of Alzheimer's disease (AD) in subjects with mild cognitive impairment (MCI). Twenty MCI patients underwent baseline and follow-up investigations of rCMRGlu, as measured by PET, and cognitive function measured by neuropsychological test assessments. Subjects were clinically followed up with an average interval of 36.5 months. Two groups were obtained after the second clinical assessment. Nine patients were diagnosed as AD and classified as progressive MCI (P-MCI), whereas 11 patients remained clinically stable and were classified as stable MCI (S-MCI). There were no differences in demographic variables or baseline MMSE between the two subgroups. Logistic regression indicated the two variables that most effectively predicted future development of AD were rCMRGlu from the left temporoparietal area and performance on the block design. These combined measures gave an optimal 90% correct classification rate, whereas only rCMRGlu or neuropsychology alone gave 75% and 65% correct classification, respectively. Measures of temporoparietal cerebral metabolism and visuospatial function may aid in predicting the evolution to AD for patients with MCI. NeuroReport 12:851-855 (C) 2001 Lippincott Williams & Wilkins.